Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis. The company was founded in 2015 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-822-5600
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees24
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions
What is Kezar Life Sciences' stock symbol?
Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."
How were Kezar Life Sciences' earnings last quarter?
Kezar Life Sciences Inc (NASDAQ:KZR) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. View Kezar Life Sciences' Earnings History.
When is Kezar Life Sciences' next earnings date?
What price target have analysts set for KZR?
4 Wall Street analysts have issued 1-year target prices for Kezar Life Sciences' shares. Their predictions range from $23.00 to $30.00. On average, they anticipate Kezar Life Sciences' share price to reach $26.50 in the next twelve months. This suggests a possible upside of 31.9% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.
What is the consensus analysts' recommendation for Kezar Life Sciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.
Has Kezar Life Sciences been receiving favorable news coverage?
Headlines about KZR stock have been trending somewhat negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kezar Life Sciences earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Kezar Life Sciences' key competitors?
Some companies that are related to Kezar Life Sciences include Prestige Consumer Healthcare (PBH), Innoviva (INVA), Endo International (ENDP), Cambrex (CBM), Heron Therapeutics (HRTX), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Corcept Therapeutics (CORT), Mallinckrodt (MNK), Phibro Animal Health (PAHC), Apellis Pharmaceuticals (APLS), Theravance Biopharma (TBPH) and Epizyme (EPZM).
What other stocks do shareholders of Kezar Life Sciences own?
Who are Kezar Life Sciences' key executives?
Kezar Life Sciences' management team includes the folowing people:
- Mr. John Fowler, Co-Founder, CEO & Director (Age 47)
- Dr. Christopher J. Kirk, Co-Founder, Pres, Chief Scientific Officer & Director (Age 47)
- Dr. Jack Taunton, Co-Founder
- Mr. Marc L. Belsky, CFO & Sec. (Age 64)
- Michael Wolfe, Director of Fin. & Operations
When did Kezar Life Sciences IPO?
(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.
Who are Kezar Life Sciences' major shareholders?
Kezar Life Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.42%), BlackRock Inc. (3.32%), Victory Capital Management Inc. (1.17%), Slow Capital Inc. (1.08%), Northern Trust Corp (0.66%) and Marshall Wace LLP (0.21%). Company insiders that own Kezar Life Sciences stock include Franklin M Berger and Morningside Venture Investment. View Institutional Ownership Trends for Kezar Life Sciences.
Which institutional investors are selling Kezar Life Sciences stock?
Which institutional investors are buying Kezar Life Sciences stock?
KZR stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Slow Capital Inc., Northern Trust Corp, Marshall Wace LLP, Charles Schwab Investment Management Inc., Rhumbline Advisers, Spark Investment Management LLC and Ironsides Asset Advisors LLC. Company insiders that have bought Kezar Life Sciences stock in the last two years include Franklin M Berger and Morningside Venture Investment. View Insider Buying and Selling for Kezar Life Sciences.
How do I buy shares of Kezar Life Sciences?
Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kezar Life Sciences' stock price today?
One share of KZR stock can currently be purchased for approximately $20.09.
How big of a company is Kezar Life Sciences?
Kezar Life Sciences has a market capitalization of $384.12 million. The company earns $-23,170,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.
What is Kezar Life Sciences' official website?
How can I contact Kezar Life Sciences?
Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]
MarketBeat Community Rating for Kezar Life Sciences (NASDAQ KZR)
MarketBeat's community ratings are surveys of what our community members think about Kezar Life Sciences and other stocks. Vote "Outperform" if you believe KZR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZR will underperform the S&P 500 over the long term. You may vote once every thirty days.
